Johnson & Johnson (J&J) has reported sales of $15.6bn for the first quarter of 2010, an increase of 4%, compared to $15.02bn for the comparable period in 2009, due to favorable currency exchange rates.
Subscribe to our email newsletter
Domestic sales declined 5%, while international sales increased 14.4%, reflecting operational growth of 5.5% and a positive currency impact of 8.9%.
Johnson & Johnson posted a net income of $4.5bn, or $1.62 per diluted share, for the first quarter 2010, compared to $3.5bn, or $1.26 per diluted share, for the prior year period.
Net earnings and diluted earnings per share were $4.5bn and $1.62, respectively. First-quarter 2010 net earnings included an after-tax gain of $910m representing the net impact of litigation matters.
Excluding this special item, net earnings for the current quarter were $3.6bn and diluted earnings per share were $1.29, representing increases of 3.1% and 2.4%, respectively, as compared to the same period in 2009.
William Weldon, chairman and CEO of J&J, said: “Thanks to the outstanding efforts of our people, we were able to deliver solid financial results. This was accomplished despite a major product recall and the continued impact of patent expirations. We are well positioned for future growth.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.